Loading
Donate

Hepatitis C

Get the PDF Version of this Document

Hepatitis C is a viral disease of the liver that afflicts an estimated four million Americans. Chronic hepatitis C is typically associated with fatigue, depression, joint pain and liver impairment, including cirrhosis and liver cancer.

Patients diagnosed with hepatitis C frequently report using cannabis to treat both symptoms of the disease as well as the nausea associated with antiviral therapy.[1-2] An observational study by investigators at the University of California at San Francisco (UCSF) found that hepatitis C patients who used cannabis were significantly more likely to adhere to their treatment regimen than patients who didn't use it.[3] Nevertheless, no clinical trials assessing the use of cannabinoids for this indication are available in the scientific literature.

Preclinical data indicates that the endocannabinoid system may moderate aspects of chronic liver disease[4-5] and that cannabinoids may reduce inflammation in experimental models of hepatitis.[6] Some other clinical reviews have reported a positive association between daily cannabis use and the progression of liver fibrosis (excessive tissue build up) and steatosis (excessive fat build up) in select hepatitis C patients.[7-9] However, more recent trial data reports that cannabis smoking is not associated with the promotion of liver disease in Hep C subjects.[10]

Experts possess divergent opinions regarding the therapeutic use of cannabinoids for hepatitis C treatment. Writing in the October 2006 issue of the European Journal of Gastroenterology, investigators from Canada and Germany concluded that cannabis' "potential benefits of a higher likelihood of treatment success [for hepatitis c patients] appear to outweigh [its] risks."[11] By contrast, other experts discourage the use of cannabis in patients with chronic hepatitis until further studies are performed.[12-16]

REFERENCES

[1] Schnelle et al. 1999. Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forschende Komplementarmedizin (Germany) 3: 28-36.

[2] David Berstein. 2004. “Hepatitis C – Current state of the art and future directions.” MedScape Today.

[3] Sylvestre et al. 2006. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology & Hepatology. 18: 1057-1063.

[4] Zamora-Valdes et al. 2005. The endocannabinoid system in chronic liver disease (PDF). Annals of Hepatology 4: 248-254.

[5] Gabbey et al. 2005. Endocannabinoids and liver disease – review. Liver International 25: 921-926.

[6] Lavon et al. 2003. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Molecular Pharmacology 64: 1334-1344.

[7] Hezode et al. 2005. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42: 63-71.

[8] Ishida et al. 2008. Influence of cannabis use on severity of hepatitis C disease. Clinical Gastroenterology and Hepatology 6: 69-75.

[9] Parfieniuk and Flisiak. 2008. Role of cannabinoids in liver disease. World Journal of Gastroenterology 14: 6109-6114.

[10] Brunet et al. 2013. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clinical Infectious Diseases 57: 663-670.

[11] Fischer et al. 2006. Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. European Journal of Gastroenterology & Hepatology. 18: 1039-1042.

[12] Schwabe and Siegmund. 2005. op. cit.

[13] Hezode et al. 2005. op. cit.

[14] David Berstein. 2004. op. cit.

[15] Hezode et al. 2008. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134: 432-439.

[16] Purohit et al. 2010. Role of cannabinoids in the development of fatty liver (steatosis). The AAPS Journal 12: 233-237.





Shop at AmazonSmile